C57bl 6 recipients

Mouse BCR-ABL⁺Arf^−/−Luciferase⁺ B-ALL cells were injected (2×10⁵) into non-conditioned, 6–8 week-old, female C57BL/6 recipients (Jackson Laboratory). Five days after the transfer, recipients were treated with DHA and ABT-263 by oral gavage. ABT-263 was formulated in a mixture of 60% Phosal 50 PG, 30% PEG 400, and 10% EtOH and dosed at 100 mg/kg/day as previously described (28 (link)). DHA was formulated in 0.5% carboxymethylcellulose, 0.5% Tween-80, and 0.5% benzyl alcohol and dosed at 200 mg/kg/day. Treatment was given daily for 15 days (days 5–20) during and after which the mice were monitored. Mice were bred and utilized in accordance with SJCRHACUC. Bioluminescence imaging was assessed by Xenogen IVIS (Perkin Elmer, MA) after mice were injected with D-luciferin (Perkin Elmer) at 150 mg/kg. Images (photons/second) were quantified through application of a contour drawn around the target region and normalized to maximum luminescence activity. For ex vivo analysis of MCL-1 expression, recipient mice 10 days after transplant of 2×10⁵ mouse BCR-ABL⁺ B-ALL cells were treated with vehicle or DHA (200 mg/kg) by gavage. Four or 8 hours after treatment, splenic blast cells were isolated and subjected to immunoblotting.

BCR-ABL⁺ B-ALL were injected (2×10⁵) into non-conditioned, 6–8-week-old, female C57BL/6 recipients (Jackson Laboratory). Five days after the transfer, recipients were treated with BTdCPU via intraperitoneal route and ABT-263 by oral gavage. Navitoclax was formulated in a mixture of 60% Phosal 50 PG, 30% PEG 400, and 10% EtOH and dosed at 100 mg/kg/day as previously described (37 (link)). 400 mg/kg/day of BTdCPU was administered in 30 μL DMSO. Treatment was given daily for 14 days (days 5–18 after leukemia injection) during and after which the mice were monitored. Mice were bred and utilized in accordance with SJCRHACUC.